Latest Conference Articles

Combination Regimen’s Timing Studied for Patients With CLL/SLL

Combination Regimen’s Timing Studied for Patients With CLL/SLL

June 15th 2021, 1:30pm

ASCO Annual Meeting

The study examining venetoclax and obinutuzumab is in progress and currently recruiting patients who are newly diagnosed with asymptomatic, high-risk CLL.

New Results From Capmatinib Study Show Promise for Patient Outcomes

New Results From Capmatinib Study Show Promise for Patient Outcomes

June 9th 2021, 8:23pm

ASCO Annual Meeting

Data were presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Conference.

Acalabrutinib Demonstrated Fewer Incidences of Atrial Fibrillation Versus Ibrutinib in Previously Treated Patients With Chronic Lymphocytic Leukemia

Acalabrutinib Demonstrated Fewer Incidences of Atrial Fibrillation Versus Ibrutinib in Previously Treated Patients With Chronic Lymphocytic Leukemia

June 9th 2021, 6:58pm

ASCO Annual Meeting

Data from a phase 3 trial comparing acalabrutinib against ibrutinib in adults with previously treated CLL showed acalabrutinib presented with non-inferior PFS and significantly fewer events of atrial fibrillation.

Survival Benefits, Established Safety Profile of Single-agent Ibrutinib for CLL Reinforced in Long-term Phase 3 Study

Survival Benefits, Established Safety Profile of Single-agent Ibrutinib for CLL Reinforced in Long-term Phase 3 Study

June 9th 2021, 4:58pm

ASCO Annual Meeting

Phase 3 data presented at the 2021 ASCO Annual Meeting have reinforced the long-term survival benefits and well-established safety profile of single-agent ibrutinib for patients with CLL.

Study Data Shows Nivolumab Improves Overall Survival in Unresectable Advanced, Metastatic Esophageal Squamous Cell Carcinoma

Study Data Shows Nivolumab Improves Overall Survival in Unresectable Advanced, Metastatic Esophageal Squamous Cell Carcinoma

June 9th 2021, 12:28pm

ASCO Annual Meeting

Nivolumab and ipilimumab is the first dual immunotherapy combination to demonstrate a superior survival benefit compared to chemotherapy in this setting.

Treatment Developments in Castration-Resistant Metastatic Prostate Cancer

Treatment Developments in Castration-Resistant Metastatic Prostate Cancer

June 9th 2021, 12:16pm

ASCO Annual Meeting

Patients with prostate cancer have to be approached differently depending on the state of their metastases.

New Data Demonstrate Significant Improvement in Hematologic Complete Response with Combination Therapy in Certain Patients With Light Chain Amyloidosis

New Data Demonstrate Significant Improvement in Hematologic Complete Response with Combination Therapy in Certain Patients With Light Chain Amyloidosis

June 8th 2021, 3:31pm

ASCO Annual Meeting

Analysis from the phase 3 ANDROMEDA study also shows doubling rates of organ response with no new safety signals for patients taking daratumumab and hyaluronidase-fihj.

Developing CAR T-Cell Therapies Offer Treatment Opportunities for Mantle Cell Lymphoma

Developing CAR T-Cell Therapies Offer Treatment Opportunities for Mantle Cell Lymphoma

June 8th 2021, 3:04pm

ASCO Annual Meeting

Although historic study results with mantel cell lymphoma showed discouraging findings, new CAR T-cell therapies routinely show between 40% and 50% of patients respond long-term without relapsing.

Novel Targeted Therapies Present Opportunities in Multiple Cancer Types

Novel Targeted Therapies Present Opportunities in Multiple Cancer Types

June 8th 2021, 2:55pm

ASCO Annual Meeting

Investigative and newly approved drugs targeting RET activity and KRAS-related mutations are showing deep, durable responses in several types of cancers.

Choosing the Right Checkpoint Inhibitor Combination Therapy for First-Line Advanced Non–Small Cell Lung Cancer

Choosing the Right Checkpoint Inhibitor Combination Therapy for First-Line Advanced Non–Small Cell Lung Cancer

June 8th 2021, 2:40pm

ASCO Annual Meeting

While discussing a few case studies, the panel was able to make appropriate treatment decisions for each patient and emphasized the importance of communicating with patients as a physician.